Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

This is an interventional treatment trial for Contact Lens Dry Eye focused on measuring contact lens, discomfort, dry eye Read More

Inclusion Criteria:

• Has provided informed consent.
• Age ≥ 18 years.
• Have a diagnosis of CLDE based on Contact Lens Dry Eye Questionnaire (CLDEQ) results:

Answer to question #10 of "Yes" and score >-0.13, or Answer to Question #10 of "No" and score > 1.27, or Answer to #10 of "Unsure" and score > 1.44

• Have a score of ≥ 2 on the Ocular Dryness Assessment at Visit 1.
• Are willing and able to follow instructions and can be present for the required study visits for the duration of the study.
• Are willing to avoid restricted medications for the time frames indicated during the study.
• Wears soft contact lenses at least 4 days a week for at least 5 hours per day using the same brand of contact lenses for at least the last 30 days.

Exclusion Criteria:

• Have a history of significant adverse reaction to lifitegrast or other components of the drug product, or contraindication to the use of lifitegrast or other components of the drug product.
• Have changed the brand or material or design of soft contact lenses or care solutions within 30 days prior to screening or anticipates the need to change current type/brand of contact lenses or care solutions throughout the 84-day study.
• Use contact lenses overnight.
• Use rigid gas permeable contact lenses or hybrid lenses.
• Have any uncontrolled systemic diseases that in the investigator's opinion could be expected to interfere with the study.
• Have had cauterization of the punctum or have had punctal plugs (silicone or collagen) inserted or removed within the 90 days prior to the screening.
• Have any active ongoing ocular infection, ocular disease or condition that would require treatment with topical ophthalmic medications.
• Require any topically delivered ophthalmic medication for any condition during the study. This includes any preserved or unpreserved rewetting drops or artificial tears. The subject must not have used ophthalmic prescription medications for at least 30 continuous days prior to Visit 1, and must not have used rewetting drops or artificial tears for at least 5 continuous days prior to Visit 1.
• Have recently started taking omega-3 fatty acids supplements within the past 2 months.
• Are taking Omega-3 fatty acids supplements but unable to maintain consistent dosage for the duration of the study.
• Are unwilling or unable to comply with the protocol.
• Have been exposed to any investigational drug within the preceding 30 days.
• Are an employee of the site that is directly involved in the management, administration, or support of this study or be an immediate family member of the same.
• If female, participant must be non-pregnant and non-lactating, and those of childbearing potential must be using an acceptable method of birth control (i.e. an Intrauterine Contraceptive Device with failure rate of <1%, hormonal contraceptives, or a barrier method.) If a female subject is abstinent, she must agree to use one of the acceptable contraceptive methods if she becomes sexually active.
• Have a clinically significant ophthalmic abnormality, infection, or disease noted by subject history or examination that would otherwise contraindicate contact lens wear and/or the use of lifitegrast (i.e., ≤ grade 3 giant papillary conjunctivitis, active ocular allergies, conjunctivitis, keratitis, uveitis).
• Have had a history of corneal surgery (corneal transplants, LASIK, PRK).